Activision, Dollar General, DuPont 12-month price targets raised by analysts, Y-mAbs Therapeutics initiated at "Outperform" at Wedbush

Activision, Dollar General, DuPont 12-month price targets raised by analysts, Y-mAbs Therapeutics initiated at “Outperform” at Wedbush

Written by Miroslav Marinov

Miroslav Marinov

Miroslav Marinov, a financial news editor at TradingPedia, is engaged with observing and reporting on the tendencies in the Foreign Exchange Market, as currently his focus is set on the major currencies of eight developed nations worldwide.

, | Updated: October 30, 2024

Activision Blizzard (ATVI)

BMO Capital Markets on Wednesday upgraded Activision Blizzard to “Outperform”, as it cited a “stronger conviction that the company’s restructuring efforts and investments in core games like Call of Duty and World of Warcraft will generate an improvement in financial performance.” The brokerage firm also revised up its 12-month price target on the stock from $43 to $60.

Shares of Activision Blizzard Inc closed higher for a second consecutive trading session on NASDAQ on Wednesday. It has also been the sharpest daily surge since August 27th. The stock went up 4.78% ($2.44) to $53.50, after touching an intraday high at $53.62, or a price level not seen since November 15th 2018 ($53.67).

Dollar General Corporation (DG)

Oppenheimer on Wednesday maintained an “Outperform” rating on Dollar General Corp and also raised its price target from $150 to $180 per share.

Dollar General shares closed higher for the sixth time in the past eleven trading sessions in New York on Wednesday. The stock went up 1.39% ($2.17) to $157.80, after touching an intraday high at $158.17, or a price level not seen since August 30th ($158.91).

DuPont de Nemours Inc (DD)

Morgan Stanley on Wednesday maintained an “Overweight” rating on DuPont Inc and raised its price target from $78 to $85 per share.

DuPont shares closed higher for the fifth time in the past eleven trading sessions in New York on Wednesday. The stock went up 1.53% ($1.03) to $68.48, after touching an intraday high at $69.00, or a price level not seen since August 30th ($69.37).

Y-mAbs Therapeutics Inc (YMAB)

Wedbush on Wednesday initiated Y-mAbs Therapeutics Inc at “Outperform” and also assigned a 12-month price target of $38 on the stock.

Shares of Y-mAbs Therapeutics Inc closed higher for the sixth time in the past eleven trading sessions on NASDAQ on Wednesday. It has also been the sharpest daily surge since August 16th. The stock went up 2.90% ($0.74) to $26.29, after touching an intraday low at $25.49 and an intraday high at $26.50.

Related News